Portal de Periódicos da CAPES

Artigo Acesso aberto Produção Nacional Revisado por pares

BIBTEX RIS

Primary cutaneous lymphoma: recommendations for clinical trial design and staging update from the ISCL, USCLC, and EORTC

2021; Elsevier BV; Volume: 140; Issue: 5 Linguagem: Inglês

10.1182/blood.2021012057

1528-0020

Elise A. Olsen, Sean Whittaker, Rein Willemze, Lauren Pinter‐Brown, Francine M. Foss, Larisa J. Geskin, Lawrence Schwartz, Sarah McCue Horwitz, Joan Guitart, John A. Zic, Youn H. Kim, Gary S. Wood, Madeleine Duvic, Wei Ai, Michael Girardi, Alejandro A. Gru, Emmanuella Guenova, Emmilia Hodak, Richard T. Hoppe, Werner Kempf, Ellen Kim, Mary Jo Lechowicz, Pablo L. Ortiz‐Romero, Evangelia Papadavid, Pietro Quaglino, Mark R. Pittelkow, H. Miles Prince, José Antônio Sanches, Makoto Sugaya, Maarten H. Vermeer, Jasmine M. Zain, Robert Knobler, Rudolf Stadler, M. Bagot, Julia Scarisbrick,

Nail Diseases and Treatments

The number of patients with primary cutaneous lymphoma (PCL) relative to other non-Hodgkin lymphomas (NHLs) is small and the number of subtypes large. Although clinical trial guidelines have been published for mycosis fungoides/Sézary syndrome, the most common type of PCL, none exist for the other PCLs. In addition, staging of the PCLs has been evolving based on new data on potential prognostic factors, diagnosis, and assessment methods of both skin and extracutaneous disease and a desire to align the latter with the Lugano guidelines for all NHLs. The International Society for Cutaneous Lymphomas (ISCL), the United States Cutaneous LymphomaConsortium (USCLC), and the Cutaneous Lymphoma Task Force of the European Organization for the Research and Treatment of Cancer (EORTC) now propose updated staging and guidelines for the study design, assessment, endpoints, and response criteria in clinical trials for all the PCLs in alignment with that of the Lugano guidelines. These recommendations provide standardized methodology that should facilitate planning and regulatory approval of new treatments for these lymphomas worldwide, encourage cooperative investigator-initiated trials, and help to assess the comparative efficacy of therapeutic agents tested across sites and studies.